恩替卡韦联合安络化纤丸治疗慢性乙型肝炎肝纤维化的效果观察

Effects of Entecavir combined with Anluohuaxian pills on chronic hepatitis B-induced liver fibrosis

目的:观察恩替卡韦联合安络化纤丸治疗慢性乙型肝炎肝纤维化的效果。方法:选取68例慢性乙型肝炎肝纤维化患者作为研究对象,根据随机数字表法将其分为对照组和观察组各34例,对照组口服恩替卡韦治疗,观察组在对照组的基础上联合安络化纤丸治疗,两组均治疗14 d,比较两组乙型肝炎病毒(HBV)DNA阴转率、治疗前后血清肝纤维化指标[透明质酸(HA)、Ⅳ型胶原(C-Ⅳ)、层粘连蛋白(LN)、IU型前胶原(PCⅢ)]水平、肝功能指标[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)]水平及不良反应发生率。结果:治疗后两组HBV-DNA阴转率与不良反应发生率比较,差异均无统计学意义(P>0.05);治疗前两组HA、C-Ⅳ、LN、PCⅢ的水平比较,差异无统计学意义(P>0.05),治疗后两组HA、C-Ⅳ、PCⅢ、LN水平明显低于治疗前,且观察组HA、C-Ⅳ、PCⅢ的水平明显低于对照组,差异均有统计学意义(P<0.05);治疗前两组ALT、AST水平比较,差异无统计学意义(P>0.05);治疗后两组ALT、AST水平均明显低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论:恩替卡韦联合安络化纤丸治疗慢性乙型肝炎肝纤维化的效果优于单纯恩替卡韦治疗效果。

Objective:To investigate effects of Entecavir combined with Anluohuaxian pills on chronic hepatitis B-induced liver fibrosis.Methods:68 patients with chronic hepatitis B-induced liver fibrosis were enrolled as the research subjects,and were divided into control group and observation group according to the random number table method,34 cases in each.The control group was treated with Entecavir orally,while the observation group was treated with Anluohuaxian pills on the basis of that of the control group.Both groups were treated for 14 days.Then,the hepatitis B virus(HBV) DNA negative conversion rate,serum fibrosis index before and after the treatment [hyaluronic acid(HA),type IV collagen(C-IV),laminin(LN),IU type procollagen(PCIII)] levels,liver function indicators [alanine aminotransferase(ALT),aspartate aminotransferase(AST)] levels and incidence of adverse reactions were compared between the two groups.Results:After the treatment,there were no statistical differences in the HBV-DNA negative conversion rate and incidence of adverse reactions between the two groups.Also,there were no statistical differences in the levels of HA,C-IV,LN and PCIII between the two groups before the treatment.However,after the treatment,the levels of HA,C-IV,PCIII and LN in the two groups were significantly lower than those before the treatment,those in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).Before the treatment,there were no statistical differences in the ALT and AST levels between the two groups.However,after the treatment,the levels of ALT and AST in the two groups were significantly lower than those before the treatment,those in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05) Conclusions:Entecavir combined with Anluohuaxian pills in the treatment of chronic hepatitis B-induced liver fibrosis is superior to single Entecavir.